-+ 0.00%
-+ 0.00%
-+ 0.00%

Deutsche Bank Upgrades ACADIA Pharmaceuticals to Buy, Raises Price Target to $35

Benzinga·05/21/2025 14:36:48
Listen to the news
Deutsche Bank analyst David Hoang upgrades ACADIA Pharmaceuticals (NASDAQ:ACAD) from Hold to Buy and raises the price target from $20 to $35.